Asset
NARSOPLIMAB
Omeros Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02682407 | phase2 | terminated | 2016-03-10 | 2020-08-25 | Omeros Corporation | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 |
| NCT03205995 | phase3 | terminated | 2018-05-02 | 2021-02-02 | Omeros Corporation | Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome |
| NCT02222545 | phase2 | completed | 2014-11-02 | 2020-01-30 | Omeros Corporation | Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies |
| NCT03608033 | phase3 | terminated | 2018-04-05 | 2024-01-12 | Omeros Corporation | Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy |
FDA applications (0)
This company has no applications containing this asset.